Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Oliver Higuera"'
Autor:
Javier Guijarro-Eguinoa, Sara Arjona-Hernandez, Stefan Stewart, Olga Pernia, Pedro Arias, Itsaso Losantos-García, Tania Rubio, Miranda Burdiel, Carlos Rodriguez-Antolin, Patricia Cruz-Castellanos, Oliver Higuera, Alberto M. Borobia, Sonia Rodriguez-Novoa, Javier de Castro-Carpeño, Inmaculada Ibanez de Caceres, Rocio Rosas-Alonso
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 12, p 9843 (2023)
Platin-based chemotherapy is the standard treatment for patients with non-small cell lung cancer (NSCLC). However, resistance to this therapy is a major obstacle in successful treatment. In this study, we aimed to investigate the impact of several ph
Externí odkaz:
https://doaj.org/article/0e5fbe9e69d44576a788296407aa5978
Autor:
Xabier Mielgo-Rubio, Virginia Calvo, Javier Luna, Jordi Remon, Margarita Martín, Pedro Berraondo, José Ramón Jarabo, Oliver Higuera, Esther Conde, Javier De Castro, Mariano Provencio, Florentino Hernando Trancho, Fernando López-Ríos, Felipe Couñago
Publikováno v:
Cancers, Vol 12, Iss 11, p 3459 (2020)
Despite numerous advances in targeted therapy and immunotherapy in the last decade, lung cancer continues to present the highest mortality rate of all cancers. Targeted therapy based on specific genomic alterations, together with PD-1 and CTLA-4 axis
Externí odkaz:
https://doaj.org/article/b8da04d99e494566a52850faedfe3d55
Autor:
Rosas-Alonso, Javier Guijarro-Eguinoa, Sara Arjona-Hernandez, Stefan Stewart, Olga Pernia, Pedro Arias, Itsaso Losantos-García, Tania Rubio, Miranda Burdiel, Carlos Rodriguez-Antolin, Patricia Cruz-Castellanos, Oliver Higuera, Alberto M. Borobia, Sonia Rodriguez-Novoa, Javier de Castro-Carpeño, Inmaculada Ibanez de Caceres, Rocio
Publikováno v:
International Journal of Molecular Sciences; Volume 24; Issue 12; Pages: 9843
Platin-based chemotherapy is the standard treatment for patients with non-small cell lung cancer (NSCLC). However, resistance to this therapy is a major obstacle in successful treatment. In this study, we aimed to investigate the impact of several ph
Immunotherapy combinations and chemotherapy sparing schemes in first line non-small cell lung cancer
Autor:
María Sereno, Oliver Higuera, Patricia Cruz Castellanos, Sandra Falagan, Xabier Mielgo-Rubio, Juan Carlos Trujillo-Reyes, Felipe Couñago
Publikováno v:
World Journal of Clinical Oncology
In recent years, studies have explored different combinations of immunotherapy and chemotherapy. The rationale behind these is the improved survival outcomes of new immunologic therapies used in first-line-treatment of advanced non-small cell lung ca
Autor:
Gómez, Oliver Higuera, Paul, Amaia Moreno, Granados, Ana Laura Ortega, Martínez, Silverio Ros, Parente, Diego Pérez, Gracia, Pedro Ruiz, Cuervo-Arango, Lucía Sáenz, Vilà, Laia
Publikováno v:
Cancer Management & Research; Jun2021, Vol. 13, p4665-4670, 6p
Autor:
Virginia Calvo, Florentino Hernando Trancho, José Ramón Jarabo, Esther Conde, Felipe Couñago, Pedro Berraondo, Fernando Lopez-Rios, Jordi Remon, Mariano Provencio, Javier Ras Luna, Javier de Castro, Xabier Mielgo-Rubio, Oliver Higuera, Margarita Martín
Publikováno v:
Cancers
ABACUS. Repositorio de Producción Científica
Universidad Europea (UEM)
Cancers, Vol 12, Iss 3459, p 3459 (2020)
ABACUS. Repositorio de Producción Científica
Universidad Europea (UEM)
Cancers, Vol 12, Iss 3459, p 3459 (2020)
Simple Summary In recent years there has been a trend towards an increase in the proportion of non-small cell lung cancer patients diagnosed with localized stage instead of advanced. However, 5-year survival rates continue to be low, even among patie
Autor:
Lucía Sáenz Cuervo-Arango, Laia Vilà, Silverio Ros Martínez, Amaia Moreno Paul, Diego Pérez Parente, Pedro Ruiz Gracia, Oliver Higuera Gómez, Ana Laura Ortega Granados
Publikováno v:
BASE-Bielefeld Academic Search Engine
Cancer Management and Research
Cancer Management and Research
Purpose Identifying patient characteristics that define a worse disease prognosis or "high tumor burden" (HTB) status is essential for clinical decision-making and treatment selection in metastatic non-small cell lung cancer (mNSCLC). We aimed to def
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::327ca0eb7c8e6e3b9f35ef3e380c0dc4
https://www.dovepress.com/high-tumor-burden-in-metastatic-non-small-cell-lung-cancer-defining-th-peer-reviewed-fulltext-article-CMAR
https://www.dovepress.com/high-tumor-burden-in-metastatic-non-small-cell-lung-cancer-defining-th-peer-reviewed-fulltext-article-CMAR